Additional file 5: of Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

  • Narendra Bharathy (Contributor)
  • Noah Berlow (Creator)
  • Eric Wang (Creator)
  • Jinu Abraham (Contributor)
  • Teagan P. Settelmeyer (Creator)
  • Jody E. Hooper (Creator)
  • Matthew N. Svalina (Creator)
  • Zia Bajwa (Creator)
  • Martin W. Goros (Creator)
  • Brian S. Hernandez (Creator)
  • Johannes E. Wolff (Creator)
  • Ranadip Pal (Contributor)
  • Angela M. Davies (Creator)
  • Arya Ashok (Contributor)
  • Darnell Bushby (Creator)
  • Maria Mancini (Creator)
  • Christopher Noakes (Creator)
  • Neal C. Goodwin (Creator)
  • Peter Ordentlich (Creator)
  • James Keck (Creator)
  • Douglas S. Hawkins (Creator)
  • Erin R. Rudzinski (Creator)
  • Atiya Mansoor (Contributor)
  • Theodore J. Perkins (Creator)
  • Christopher R. Vakoc (Creator)
  • Joel E Michalek (Creator)
  • Charles Keller (Creator)
  • Angela M. Davies (Creator)
  • Douglas Hawkins (Creator)



Figure S5. Representative immunohistochemistry for CD68 of mouse eRMS tissue and primary cells. Necrotic tissue (a) showed few macrophages present, while viable tumor (b) showed a collection of many macrophages. Macrophage presence was observed as being the same for all treatment groups. (TIF 2929 kb)
Date made available2019

Cite this